english.prescrire.org > Topics > Advancing healthcare policy > Drug packaging and patient safety > Actions > Proposed recommendations on drug brand names by France's Health Products Agency maintain dangerous confusion (12/2016)

Advancing healthcare policy

Drug packaging and patient safety

Advancing healthcare policy

Drug packaging and patient safety: Actions
The proposed recommendations on drug brand names by France's Health Products Agency: a plan that maintains dangerous name confusion (December 2016)

Paris, 14 December 2016

Prescrire urges the French Health Products Agency (ANSM) to revise its draft recommendations on drug brand names in a way that maximises patient safety, abandoning national practices of brand names and labelling consisting of a hotchpotch of terms that cause medication errors by creating confusion. The ANSM is also urged to stop legitimising the continued presence of umbrella brands on the market, given the dangers they pose for patients, by challenging their regulatory compliance.

> Click here to download Prescrire's response (pdf, 226 Ko)

Advancing healthcare policy

Drug packaging and patient safety

Advancing healthcare policy

Drug packaging and patient safety: Actions The proposed recommendations on drug brand names by France's Health Products Agency: a plan that maintains dangerous name confusion (December 2016)

Drug packaging and patient safety: Actions
The proposed recommendations on drug brand names by France's Health Products Agency: a plan that maintains dangerous name confusion (December 2016)